130 related articles for article (PubMed ID: 31634551)
1. Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe.
Delattre IK; Briquet C; Wallemacq P; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2020 Jan; 55(1):105825. PubMed ID: 31634551
[TBL] [Abstract][Full Text] [Related]
2. Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.
Agudelo M; Rodriguez CA; Pelaez CA; Vesga O
Antimicrob Agents Chemother; 2014; 58(2):1005-18. PubMed ID: 24277034
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
[TBL] [Abstract][Full Text] [Related]
4. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
5. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
[TBL] [Abstract][Full Text] [Related]
6. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
[TBL] [Abstract][Full Text] [Related]
7. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
9. Relative potency of different generic brands of meropenem, colistin and fosfomycin: Implications for antimicrobial therapy and antimicrobial formulary.
Das P; Jana B; Dhar K; Goel G; Bhattacharya S; Chandy M
Indian J Med Microbiol; 2019; 37(1):95-98. PubMed ID: 31424016
[TBL] [Abstract][Full Text] [Related]
10. The impact of efflux pumps on meropenem susceptibility among metallo-β-lactamase-producing and nonproducing Pseudomonas aeruginosa: Insights for better antimicrobial stewardship.
Perez LRR
Infect Control Hosp Epidemiol; 2019 Aug; 40(8):957-958. PubMed ID: 31190675
[No Abstract] [Full Text] [Related]
11. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY Participants.
Fluit AC; Verhoef J; Schmitz FJ
Eur J Clin Microbiol Infect Dis; 2000 May; 19(5):370-4. PubMed ID: 10898140
[TBL] [Abstract][Full Text] [Related]
12. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
[TBL] [Abstract][Full Text] [Related]
13. Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.
Motos A; Avery LM; DeRonde KJ; Mullane EM; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2019 May; 53(5):698-702. PubMed ID: 30880231
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group.
Goossens H
Clin Microbiol Infect; 2003 Sep; 9(9):980-3. PubMed ID: 14616692
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
[TBL] [Abstract][Full Text] [Related]
16. Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures.
Franceschi L; Cojutti P; Baraldo M; Pea F
Ther Drug Monit; 2014 Oct; 36(5):674-6. PubMed ID: 24637698
[TBL] [Abstract][Full Text] [Related]
17. Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
Sabet M; Tarazi Z; Griffith DC
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323049
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [
